Roivant Sciences Ltd.
ROIV
$11.01
$0.010.09%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 101.52% | -43.99% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 101.52% | -43.99% | |||
| Cost of Revenue | -0.89% | 18.91% | |||
| Gross Profit | 4.23% | -23.44% | |||
| SG&A Expenses | 12.94% | 26.01% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.38% | 22.03% | |||
| Operating Income | -3.69% | -24.61% | |||
| Income Before Tax | -4.51% | -1,042.48% | |||
| Income Tax Expenses | -305.23% | 4.14% | |||
| Earnings from Continuing Operations | 11.78% | -649.43% | |||
| Earnings from Discontinued Operations | 859.05% | -148.36% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 3.15% | 31.56% | |||
| Net Income | 173.59% | -341.54% | |||
| EBIT | -3.69% | -24.61% | |||
| EBITDA | -3.73% | -26.67% | |||
| EPS Basic | 174.89% | -341.70% | |||
| Normalized Basic EPS | -15.94% | -38.85% | |||
| EPS Diluted | 174.28% | -358.68% | |||
| Normalized Diluted EPS | -15.94% | -38.85% | |||
| Average Basic Shares Outstanding | -1.73% | -0.05% | |||
| Average Diluted Shares Outstanding | -1.73% | -0.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||